Statistical Due Diligence
Having a statistical expert on your side in life sciences investments can be the difference between a bad investment and a good one. Rigorous due diligence of the statistical data in an investment can promote your team’s understanding of the validity of their statistical claims and reduce investment risk.
Public Company Investment
BioRankings® uses all relevant publicly available resources, including but not limited to published papers, poster presentations, press releases, and interviews, to analyze the investment risk.
In analyzing the data around an investment BioRankings uses many strategies, including:
Venture and Angel Investment
BioRankings works with venture and angel investors to examine the statistical data presented by a company looking for investment. Although our work with venture and angel investors is similar to our work with public companies, the ability to work directly with the researchers generating the data gives us the ability to deeply dive into the research. We work with your team, and the company looking for funding, to ensure that there is a strong data argument for the product and a plan moving forward.
Examples of past Statistical Due Diligence consultations and results
BioRankings predicted that Inhaled Remodulin would be successful before the company’s announcement.
BioRankings predicted that GPC’s Satraplatin would fail before the company’s announcement.
The BioRankings method showed the data was too close to warrant a guaranteed pass or fail for Keryx’s Sulodexide.